马来酸西布曲明(Sibutramine maleate) - 药物靶点：DAT x NET x SERT_在研适应症：神经性厌食症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

DAT x NET x SERT

作用方式

抑制剂

作用机制

多巴胺重摄取抑制剂、NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、5-羟色胺重摄取抑制剂

治疗领域

其他疾病

在研适应症

神经性厌食症

非在研适应症-

原研机构

Abbott Laboratories

在研机构

Abbott Laboratories

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

韩国 (2011-12-01),

神经性厌食症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H26ClN

InChIKeyUNAANXDKBXWMLN-UHFFFAOYSA-N

CAS号106650-56-0

查看全部结构式(2)

关联

16

项与马来酸西布曲明相关的临床试验

NCT00993421

/ Terminated临床2期

LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women

The purpose of this study is to determine if LY377604 + sibutramine work better than LY377604 or sibutramine alone in the treatment of obesity.

开始日期2009-10-01

申办/合作机构

Eli Lilly & Co.

NCT00914212

/ Completed临床1期

A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men

This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by sibutramine.

开始日期2009-05-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT01170364

/ Terminated临床4期IIT

Studying the Effects of Sibutramine on Eating Behavior

Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating behavior, cognitive functioning, and psychological functioning under sibutramine and placebo conditions.

开始日期2009-02-01

申办/合作机构

The New York State Psychiatric Institute

[+1]

100 项与马来酸西布曲明相关的临床结果

登录后查看更多信息

100 项与马来酸西布曲明相关的转化医学

登录后查看更多信息

100 项与马来酸西布曲明相关的专利（医药）

登录后查看更多信息

1,793

项与马来酸西布曲明相关的文献（医药）

2025-06-01·Food Chemistry

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

作者: Wu, Wenlin ; Huang, Xia ; Liu, Shiyao ; Chen, Xiaoqi ; Zhou, Yan ; Wan, Yuping ; Xia, Bing ; Guo, Tianrong ; Shi, Peiyu ; Xiao, Quanwei ; Zhang, Min

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

2025-05-01·Nutrition Reviews

The Effectiveness of Nonsurgical Interventions for Weight Loss Maintenance in Adults: An Updated, GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials

Review

作者: Shidfar, Farzad ; Nazarian, Amirhossein ; Hemmati, Amirhossein ; Hasan Rashedi, Minoo ; Shoaibinobarian, Nargeskhatoon ; Zeraattalab-Motlagh, Sheida ; Ghoreishy, Seyed Mojtaba ; Fernandez, Maria Luz ; Noormohammadi, Morvarid ; Movahed, Samira

AbstractContextToday, there are many discussions about the best way to maintain weight and prevent weight regain after a period of weight loss.ObjectivesThe aim of this study was to summarize, based on data from randomized clinical trials (RCTs), the impact of nonsurgical interventions for adults’ weight loss maintenance.Data SourcesThe Medline (PubMed), Scopus, and Web of Science databases were reviewed during June 2023.Data ExtractionMeta-analyses assessing the impacts of nonsurgical interventions for weight loss maintenance were conducted. Effect sizes of nutritional interventions were recalculated by applying a random-effects model. The Grading of Recommendations, Assessment, Development, and Evaluation framework was implemented to determine evidence certainty.ResultsMeta-analysis of data from a total of 56 RCTs (n = 13 270 participants) represented a significant weight reduction after behavior and lifestyle interventions (mean difference [MD], –0.64 kg [95% CI, –1.18 to –0.09]; I2 = 89.5%; P < .001 for heterogeneity). Pharmacological interventions had also a significant effect on weight change during the weight maintenance phase (MD, –2.57 kg [95% CI, –3.12 to –2.02]; I2 = 91.6%; P < .001 for heterogeneity). The weight loss reduction from pharmacological interventions was greater with sibutramine (MD, –2.57; 95% CI: –3.12 to –2.02). Additionally, diet intervention and dietary and physical activity strategies were associated with a negligible trending decrease in weigh regain (respectively: MD, –0.91 kg [95% CI, –2.18 to 0.36], I2 = 55.7%, P = .016 for heterogeneity; and MD, –0.3 kg [95% CI, –4.13 to 3.52], I2 = 94.1%, P < .001).ConclusionThe findings of this review indicate there is a favorable impact of behavior-based interventions and antiobesity medications on weight maintenance.Systematic Review RegistrationPROSPERO registration no CRD42023468056.

2025-03-04·Clinical Toxicology

Presence of sibutramine and sildenafil in weight loss dietary supplements: a case series with analytical and clinical investigation

Article

作者: Pietri, Tessa ; Carles, Marie ; Fabresse, Nicolas ; Richez, Magali ; Micallef, Joelle ; Corteggiani-Giraud, Clara ; Lacarelle, Bruno ; Solas-Chesneau, Caroline

INTRODUCTIONThe use of weight loss supplements is increasing, often driven by online marketing. However, many of these supplements are adulterated with undeclared pharmaceutical substances, potentially posing significant health risks. We investigated the presence of sibutramine and sildenafil in weight loss supplements and assessed the associated clinical outcomes.MATERIALS AND METHODSA total of 12 weight loss supplement samples (capsules, tea, and coffee bags) were analyzed using liquid chromatography-high resolution mass spectrometry. Demographic and clinical data were collected by the Marseille Regional Pharmacovigilance Centre from 29 patients who reported using these products.RESULTSAll samples were found to contain sibutramine, with concentrations ranging from 7.5 mg to 15.4 mg per unit. Sildenafil was detected in all samples, with concentrations ranging from 1.7 mg to 4.8 mg per unit. Clinical data from 29 users showed significant weight loss, with an average of 7.5 kg after 37 days of use. Adverse effects included anorexia (n = 15), tachycardia (n = 13), insomnia (n = 2) and chest pain (n = 4). In some cases, more serious effects such as seizures and dependence were observed.DISCUSSIONBoth sibutramine and sildenafil were withdrawn from the market due to cardiovascular risks. As such, the unregulated use of these products pose a serious risk to public health, particularly in individuals with underlying cardiovascular disease.CONCLUSIONWe detected sibutramine and sildenafil in all 12 weight loss supplements tested, which highlights the need for stricter regulation and monitoring.

100 项与马来酸西布曲明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A08AA10	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经性厌食症	韩国	Abbott Laboratories	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01170364 (CTgov)	临床4期	肥胖	14	Placebo+Sibutramine (Sibutramine)	願選衊淵餘鏇淵構遞鏇(願餘鹽獵積壓鏇鏇積築) = 壓醖夢艱醖醖齋糧淵淵範齋蓋襯顧夢鹹簾鏇構 (憲齋範窪窪糧夢築醖淵, 膚繭簾淵鬱憲窪顧製範 ~ 鬱餘獵網範餘觸襯鬱鹽) 更多	-	2017-07-31
				Placebo+Sibutramine (Placebo)	願選衊淵餘鏇淵構遞鏇(願餘鹽獵積壓鏇鏇積築) = 願簾網糧簾簾觸醖壓鏇範齋蓋襯顧夢鹹簾鏇構 (憲齋範窪窪糧夢築醖淵, 糧膚齋壓範構糧襯膚構 ~ 鹹觸糧艱築襯獵餘衊遞) 更多
NCT00537810 (CTgov)	临床4期	暴食症 \| 肥胖	104	Sibutramine (Sibutramine)	遞鑰簾憲觸願膚觸鏇繭(鹹願鑰遞鏇齋淵夢壓憲) = 憲夢顧艱網醖簾鑰膚簾憲憲顧窪餘衊窪鏇鏇選 (選願鏇衊鑰鹹構餘簾齋, 夢窪餘願範製襯憲積淵 ~ 獵鹽齋鑰憲窪鹽獵選網) 更多	-	2014-12-12
				Placebo (Placebo)	遞鑰簾憲觸願膚觸鏇繭(鹹願鑰遞鏇齋淵夢壓憲) = 糧繭鹹繭壓鹹獵獵範觸憲憲顧窪餘衊窪鏇鏇選 (選願鏇衊鑰鹹構餘簾齋, 醖觸壓選製襯齋餘鹽鑰 ~ 衊餘製顧鑰齋顧壓廠選) 更多
NCT00993421 (CTgov)	临床2期	肥胖	343	Placebo LY377604 (Placebo)	廠醖廠蓋鬱膚構鑰遞獵(願襯顧窪蓋構選觸糧製) = 壓艱鏇願艱鑰夢願齋窪衊夢築鑰獵獵繭襯鹽顧 (鹽簾範鏇網鏇築鹹窪糧, 齋襯鬱鹽蓋築襯鏇範蓋 ~ 糧壓築積膚遞醖鬱蓋積) 更多	-	2011-06-02
				Placebo Metoprolol+LY377604 (LY377604 (75 mg))	廠醖廠蓋鬱膚構鑰遞獵(願襯顧窪蓋構選觸糧製) = 蓋簾製鹹廠構繭鏇鑰艱衊夢築鑰獵獵繭襯鹽顧 (鹽簾範鏇網鏇築鹹窪糧, 艱膚獵選網夢願鹹艱繭 ~ 築淵觸製憲繭願蓋範鬱) 更多